Handelsbanken Fonder AB decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 49.6% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 91,630 shares of the biopharmaceutical company’s stock after selling 90,000 shares during the period. Handelsbanken Fonder AB’s holdings in Pfizer were worth $3,271,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in the company. HPM Partners LLC grew its stake in Pfizer by 1,561.3% in the 1st quarter. HPM Partners LLC now owns 106,341 shares of the biopharmaceutical company’s stock worth $3,638,000 after acquiring an additional 99,940 shares during the period. Insight 2811 Inc. grew its stake in Pfizer by 3.7% in the 1st quarter. Insight 2811 Inc. now owns 9,324 shares of the biopharmaceutical company’s stock worth $319,000 after acquiring an additional 329 shares during the period. Loudon Investment Management LLC grew its stake in Pfizer by 406.8% in the 1st quarter. Loudon Investment Management LLC now owns 47,616 shares of the biopharmaceutical company’s stock worth $1,629,000 after acquiring an additional 38,221 shares during the period. Meridian Investment Counsel Inc. grew its stake in Pfizer by 0.3% in the 1st quarter. Meridian Investment Counsel Inc. now owns 62,359 shares of the biopharmaceutical company’s stock worth $2,133,000 after acquiring an additional 213 shares during the period. Finally, Westchester Capital Management Inc. grew its stake in Pfizer by 1.1% in the 1st quarter. Westchester Capital Management Inc. now owns 179,507 shares of the biopharmaceutical company’s stock worth $6,141,000 after acquiring an additional 1,920 shares during the period. Institutional investors and hedge funds own 69.74% of the company’s stock.
PFE has been the subject of several recent analyst reports. UBS Group set a $40.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research note on Wednesday, December 6th. BMO Capital Markets reiterated a “buy” rating and issued a $39.00 price target on shares of Pfizer in a report on Friday, November 10th. Vetr upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $38.82 price target on the stock in a report on Thursday, November 23rd. Zacks Investment Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price objective on the stock in a report on Tuesday, October 3rd. Finally, Jefferies Group set a $39.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a report on Thursday, November 16th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have given a buy rating to the company’s stock. Pfizer presently has a consensus rating of “Buy” and an average target price of $38.83.
Pfizer Inc. (NYSE PFE) opened at $36.56 on Friday. Pfizer Inc. has a 12 month low of $30.90 and a 12 month high of $37.35. The company has a market cap of $217,920.00, a price-to-earnings ratio of 22.43, a PEG ratio of 2.46 and a beta of 1.01. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The company had revenue of $13.17 billion for the quarter, compared to analyst estimates of $13.17 billion. During the same quarter in the prior year, the business posted $0.61 EPS. Pfizer’s quarterly revenue was up .9% on a year-over-year basis. research analysts forecast that Pfizer Inc. will post 2.59 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd will be issued a $0.34 dividend. The ex-dividend date is Thursday, February 1st. This is an increase from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 dividend on an annualized basis and a yield of 3.72%. Pfizer’s dividend payout ratio is 78.53%.
Pfizer declared that its Board of Directors has initiated a stock repurchase plan on Monday, December 18th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the biopharmaceutical company to buy shares of its stock through open market purchases. Shares repurchase plans are often a sign that the company’s management believes its shares are undervalued.
In other Pfizer news, insider Alexander R. Mackenzie sold 14,700 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total value of $518,910.00. Following the completion of the sale, the insider now owns 117,432 shares in the company, valued at approximately $4,145,349.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Alexander R. Mackenzie sold 6,750 shares of the firm’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $37.00, for a total transaction of $249,750.00. Following the completion of the sale, the insider now owns 103,458 shares of the company’s stock, valued at approximately $3,827,946. The disclosure for this sale can be found here. Over the last three months, insiders sold 29,450 shares of company stock valued at $1,065,220. Insiders own 0.06% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Handelsbanken Fonder AB Sells 90,000 Shares of Pfizer Inc. (PFE)” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/12/pfizer-inc-pfe-shares-sold-by-handelsbanken-fonder-ab.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.